Shield Therapeutics (LSE:STX) LT-Debt-to-Total-Asset : 0.14 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shield Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.14.

Shield Therapeutics's long-term debt to total assets ratio increased from Jun. 2022 (0.00) to Jun. 2023 (0.14). It may suggest that Shield Therapeutics is progressively becoming more dependent on debt to grow their business.

Shield Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shield Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics LT-Debt-to-Total-Asset Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.27

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													-	-	-	0.27	0.14

Shield Therapeutics LT-Debt-to-Total-Asset Calculation

Shield Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	6.008	/	22.074
	=	0.27

Shield Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )	/	Total Assets (Q: Jun. 2023 )
	=	5.705	/	41.667
	=	0.14

Shield Therapeutics (LSE:STX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shield Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.